Related Experiment Video
Updated: Jun 2, 2026
Biofunctionalization of Magnetic Nanomaterials
Published on: July 16, 2020
In vitro anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide nanoparticles
Babita Gaihre1, Myung S Khil, Hak Y Kim
1School of Mechanical, Material and Mechatronic Engineering, University of Wollongong, Wollongong, NSW, Australia.
Abstract:
Magnetic drug targeting allows accumulation of drug at a defined target site with the help of an external magnetic field. Current research explored uptake and anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide particles (DXR-GIOPs) in order to investigate potential of gelatin-coated iron oxide particles (GIOPs) as a drug carrier in the field of magnetic drug targeting. The in vitro test was done using HeLa cells as a model cell and DXR as a model drug. The cytotoxicity and uptake of GIOPs were also studied and results were compared with that of DXR-GIOPs. The results indicated that GIOPs were not toxic to HeLa cells even at higher concentration of 1.2 mg/mL; however, DXR-GIOPs showed toxicity in time as well as dose-dependent manner. Furthermore, quantitative and qualitative uptake studies showed higher uptake of DXR-GIOPs compared to GIOPs in the identical condition by the cells.
Insights
Gelatin-coated magnetic iron oxide particles loaded with doxorubicin (DXR-GIOPs) show promising anticancer activity and enhanced cellular uptake for magnetic drug targeting. These DXR-GIOPs demonstrate dose- and time-dependent toxicity against HeLa cells without harming the carrier particles themselves.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
Background:
- Magnetic drug targeting utilizes external magnetic fields to concentrate therapeutic agents at specific sites.
- Gelatin-coated iron oxide particles (GIOPs) are being investigated as potential carriers for magnetic drug targeting.
- Doxorubicin (DXR) is a widely used chemotherapeutic agent.
Purpose of the Study:
- To evaluate the anticancer activity and cellular uptake of doxorubicin-loaded gelatin-coated magnetic iron oxide particles (DXR-GIOPs).
- To assess the potential of GIOPs as drug carriers in magnetic drug targeting applications.
- To compare the cytotoxicity and uptake of DXR-GIOPs with unloaded GIOPs in vitro.
Main Methods:
- In vitro study using HeLa cells as a model cancer cell line.
- Preparation and characterization of doxorubicin-loaded gelatin-coated magnetic iron oxide particles (DXR-GIOPs).
- Cytotoxicity assays and quantitative/qualitative uptake studies of GIOPs and DXR-GIOPs.
Main Results:
- Gelatin-coated iron oxide particles (GIOPs) exhibited no toxicity to HeLa cells, even at high concentrations (1.2 mg/mL).
- Doxorubicin-loaded GIOPs (DXR-GIOPs) demonstrated significant time- and dose-dependent cytotoxicity.
- HeLa cells showed higher uptake of DXR-GIOPs compared to unloaded GIOPs under identical conditions.
Conclusions:
- Gelatin-coated iron oxide particles are safe and effective carriers for doxorubicin in magnetic drug targeting.
- DXR-GIOPs show enhanced cellular uptake and potent anticancer activity, supporting their therapeutic potential.
- This study validates the use of GIOPs for targeted delivery of chemotherapeutic agents like doxorubicin.
